Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19494652rdf:typepubmed:Citationlld:pubmed
pubmed-article:19494652lifeskim:mentionsumls-concept:C0596290lld:lifeskim
pubmed-article:19494652lifeskim:mentionsumls-concept:C0242852lld:lifeskim
pubmed-article:19494652lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:19494652lifeskim:mentionsumls-concept:C1510852lld:lifeskim
pubmed-article:19494652pubmed:dateCreated2009-6-4lld:pubmed
pubmed-article:19494652pubmed:abstractTextProliferative vitreoretinopathy represents the major complication in retinal detachment surgery and occurs in about 5-15% of cases resulting in a significant loss of vision despite multiple surgical procedures. Although successful anatomical reattachment is usually achieved, the reduction in central vision often remains permanent due to the intraretinal changes induced by retinal detachment and the subsequent proliferative response within the retina. Retinal Muller glial cells play a pivotal role in this process together with retinal pigment epithelial cells which are dispersed in the vitreous and stimulated by growth factors and serum in the vitreous after the breakdown of the blood-retinal barrier.lld:pubmed
pubmed-article:19494652pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19494652pubmed:languageenglld:pubmed
pubmed-article:19494652pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19494652pubmed:citationSubsetIMlld:pubmed
pubmed-article:19494652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19494652pubmed:statusMEDLINElld:pubmed
pubmed-article:19494652pubmed:issn0250-3751lld:pubmed
pubmed-article:19494652pubmed:authorpubmed-author:LewisGeoffrey...lld:pubmed
pubmed-article:19494652pubmed:authorpubmed-author:FisherSteven...lld:pubmed
pubmed-article:19494652pubmed:authorpubmed-author:EiblKirsten...lld:pubmed
pubmed-article:19494652pubmed:copyrightInfoCopyright 2009 S. Karger AG, Basel.lld:pubmed
pubmed-article:19494652pubmed:issnTypePrintlld:pubmed
pubmed-article:19494652pubmed:volume44lld:pubmed
pubmed-article:19494652pubmed:ownerNLMlld:pubmed
pubmed-article:19494652pubmed:authorsCompleteYlld:pubmed
pubmed-article:19494652pubmed:pagination46-55lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:meshHeadingpubmed-meshheading:19494652...lld:pubmed
pubmed-article:19494652pubmed:year2009lld:pubmed
pubmed-article:19494652pubmed:articleTitleAlkylphosphocholines: a new approach to inhibit cell proliferation in proliferative vitreoretinopathy.lld:pubmed
pubmed-article:19494652pubmed:affiliationUniversity Eye Hospital, Ludwig-Maximilians-University, Munich, Germany. Kirsten.Eibl@med.uni-muenchen.delld:pubmed
pubmed-article:19494652pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19494652pubmed:publicationTypeReviewlld:pubmed
pubmed-article:19494652pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19494652pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19494652lld:pubmed